000120203 001__ 120203
000120203 005__ 20240319081016.0
000120203 0247_ $$2doi$$a10.3390/molecules27041293
000120203 0248_ $$2sideral$$a131233
000120203 037__ $$aART-2022-131233
000120203 041__ $$aeng
000120203 100__ $$aXu, Catherine K.
000120203 245__ $$aThe Pathological G51D Mutation in Alpha-Synuclein Oligomers Confers Distinct Structural Attributes and Cellular Toxicity
000120203 260__ $$c2022
000120203 5060_ $$aAccess copy available to the general public$$fUnrestricted
000120203 5203_ $$aA wide variety of oligomeric structures are formed during the aggregation of proteins associated with neurodegenerative diseases. Such soluble oligomers are believed to be key toxic species in the related disorders; therefore, identification of the structural determinants of toxicity is of upmost importance. Here, we analysed toxic oligomers of α-synuclein and its pathological variants in order to identify structural features that could be related to toxicity and found a novel structural polymorphism within G51D oligomers. These G51D oligomers can adopt a variety of β-sheet-rich structures with differing degrees of α-helical content, and the helical structural content of these oligomers correlates with the level of induced cellular dysfunction in SH-SY5Y cells. This structure–function relationship observed in α-synuclein oligomers thus presents the α-helical structure as another potential structural determinant that may be linked with cellular toxicity in amyloid-related proteins.
000120203 536__ $$9info:eu-repo/grantAgreement/ES/MCIU-FEDER/PGC2018-096335-B-100$$9info:eu-repo/grantAgreement/ES/MINECO/RYC-2012-12068
000120203 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000120203 590__ $$a4.6$$b2022
000120203 592__ $$a0.704$$b2022
000120203 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b63 / 178 = 0.354$$c2022$$dQ2$$eT2
000120203 593__ $$aPharmaceutical Science$$c2022$$dQ1
000120203 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b97 / 285 = 0.34$$c2022$$dQ2$$eT2
000120203 593__ $$aChemistry (miscellaneous)$$c2022$$dQ2
000120203 593__ $$aDrug Discovery$$c2022$$dQ2
000120203 593__ $$aPhysical and Theoretical Chemistry$$c2022$$dQ2
000120203 593__ $$aOrganic Chemistry$$c2022$$dQ2
000120203 593__ $$aAnalytical Chemistry$$c2022$$dQ2
000120203 593__ $$aMedicine (miscellaneous)$$c2022$$dQ2
000120203 593__ $$aMolecular Medicine$$c2022$$dQ3
000120203 594__ $$a6.7$$b2022
000120203 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000120203 700__ $$aCastellana-Cruz, Marta
000120203 700__ $$aChen, Serene W.
000120203 700__ $$aDu, Zhen
000120203 700__ $$aMeisl, Georg
000120203 700__ $$aLevin, Aviad
000120203 700__ $$aMannini, Benedetta
000120203 700__ $$aItzhaki, Laura
000120203 700__ $$aKnowles, Tuomas P. J.
000120203 700__ $$aDobson, Christopher
000120203 700__ $$0(orcid)0000-0002-9138-6687$$aCremades, Nunilo$$uUniversidad de Zaragoza
000120203 700__ $$aKumita, Janet R.
000120203 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000120203 773__ $$g27, 4 (2022), 1293 [14 pp.]$$pMolecules (Basel, Online)$$tMolecules$$x1420-3049
000120203 8564_ $$s4303007$$uhttps://zaguan.unizar.es/record/120203/files/texto_completo.pdf$$yVersión publicada
000120203 8564_ $$s2652738$$uhttps://zaguan.unizar.es/record/120203/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000120203 909CO $$ooai:zaguan.unizar.es:120203$$particulos$$pdriver
000120203 951__ $$a2024-03-18-15:42:12
000120203 980__ $$aARTICLE